[A21-09] Pertuzumab/trastuzumab (breast cancer, first line) - Benefit assessment according to §35a Social Code Book V
Last updated 03.05.2021
Project no.:
A21-09
Commission:
Commission awarded on 20.01.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-11 | Pertuzumab/trastuzumab (breast cancer, adjuvant) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-10 | Pertuzumab/trastuzumab (breast cancer, neoadjuvant) - Benefit assessment according to §35a Social Code Book V | Commission completed |